Skip to main content
. 2020 Feb 24;4(4):696–705. doi: 10.1182/bloodadvances.2019000492

Figure 3.

Figure 3.

Disease-free and overall survival according to KIT status. DFS (A) and OS (B) for all patients (according to KIT mutation status). DFS (C) and OS (D) for younger patients (according to KIT mutation status). DFS (E) and OS (F) for KITwt patients (according to KIT expression level). Outcomes at 36 months were calculated by using the Kaplan-Meier (KM) method.